Eighteen IPOs raised a combined $5.3 billion in April, above the 10-year historical average by deal count and proceeds (16 IPOs, $3.7B). It was the busiest month for both overall new issuance and $100+ million IPOs since November 2021. Nine deals raised $100...read more
Three IPOs priced in the first week of April, led by a sizable biotech. The calendar should see more activity coming up, thanks to some large launches and notable new filings.Neuro and inflammation biotech Contineum Therapeutics (CTNM) priced a downsized...read more
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for inflammatory diseases, raised $110 million by offering 6.9 million shares at $16, the low end of the range of $16 to $18. The company offered 1.9 million fewer shares than...read more
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday.The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of...read more
Renaissance Capital's April IPO Market Update
Eighteen IPOs raised a combined $5.3 billion in April, above the 10-year historical average by deal count and proceeds (16 IPOs, $3.7B). It was the busiest month for both overall new issuance and $100+ million IPOs since November 2021. Nine deals raised $100...read more
US IPO Weekly Recap: April IPO market gets a boost from large launches and new filings
Three IPOs priced in the first week of April, led by a sizable biotech. The calendar should see more activity coming up, thanks to some large launches and notable new filings.Neuro and inflammation biotech Contineum Therapeutics (CTNM) priced a downsized...read more
Neuro and inflammation biotech Contineum Therapeutics prices downsized IPO at $16, the low end of the range
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for inflammatory diseases, raised $110 million by offering 6.9 million shares at $16, the low end of the range of $16 to $18. The company offered 1.9 million fewer shares than...read more
Neuro and inflammation biotech Contineum Therapeutics sets terms for $150 million IPO
Contineum Therapeutics, a Phase 1 biotech developing small molecule therapies for IPF and multiple sclerosis, announced terms for its IPO on Monday.The San Diego, CA-based company plans to raise $150 million by offering 8.8 million shares at a price range of...read more